In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From IMV Inc.

Bavarian Nordic CEO 'Seeking Big Pharma partner' For RSV Vaccine Program

Phase II trials of Bavarian Nordic’s MVA-BN RSV prophylactic vaccine suggest it boosts memory responses against RSV in patients with a poor underlying immunity. Phase III trials may begin in 2020.

Analysis Clinical Trials

RSV Market: An Unmet Clinical Need For ReViral, And Big Pharma Too

The market landscape for drugs against respiratory syncytial virus infections, an important risk factor in premature infants and the immunocompromised, may change drastically in the future with numerous potential therapies in the pipeline.

Clinical Trials Research & Development

Pipeline Watch: Phase III Studies of CSL112 And RT-100 Imminent

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Pipeline Watch: Dismay With Veliparib, Tarextumab, House Dust Mite Allergens

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • ImmunoVaccine Technologies Inc.
  • Immunovaccine Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • IMV Inc.
  • Senior Management
  • Frederic Ors, CEO
    Pierre Labbe, CFO
    Gabriela Rosu, MD, CMO
    Joseph Sullivan, SVP, Bus. Dev.
  • Contact Info
  • IMV Inc.
    Phone: (902) 492-1819
    130 Eileen Stubbs Ave.
    Ste. 19
    Dartmouth, B3B 2C4
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register